Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
The Japanese Journal of Surgery|May 1, 1991
Effects of the oral or intratumoral administration of OK432 on the immuno-reactivities of regional lymph nodes in gastric cancer patientsE Yanagawa, T Toge, Y Yamaguchi, et al.
Breast Cancer Research and Treatment|June 24, 2011
Correlation between docetaxel-induced skin toxicity and the use of steroids and H₂ blockers: a multi-institution surveyK Kawaguchi, H Ishiguro, S Morita, et al.
Journal of the National Cancer Institute|January 17, 1996
Telomerase activity in human breast tumorsE Hiyama, L Gollahon, T Kataoka, et al.
Cancer Chemotherapy and Pharmacology|May 30, 2014
A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancerN Masuda, K Higaki, T Takano, et al.
Breast Cancer (Tokyo, Japan)|February 16, 2018
Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for HER2-positive primary breast cancer: a randomised, five-arm, multicentre, open-label phase II trialN Masuda, M Toi, N Yamamoto, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|March 2, 2006
Update results of FEC followed by docetaxel neoadjuvant trials for primary breast cancerS Ohnoa, M Toi, K Kuroi, et al.
Breast Cancer Research and Treatment|June 13, 2012
Predictions of the pathological response to neoadjuvant chemotherapy in patients with primary breast cancer using a data mining techniqueM Takada, M Sugimoto, S Ohno, et al.
Asia-Pacific Journal of Clinical Oncology|April 4, 2017
Toxicity profile differences of adjuvant docetaxel/cyclophosphamide (TC) between Asian and Caucasian breast cancer patientsL W C Chow, L Biganzoli, A D Leo, et al.
Breast Cancer Research and Treatment|October 15, 2013
Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil– epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapyS Ohno, L W C Chow, N Sato, et al.
Breast Cancer Research and Treatment|April 1, 2014
Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study)M Takada, H Ishiguro, S Nagai, et al.
Pageof 5